Gefitinib (Iressa®) is an inhibitor of EGFR tyrosine kinase, used in the treatment of lung and
other cancers. Its efficient use is severely hampered by very low solubility in water which can …

Background: Gefitinib, an anticancer drug, has an extremely low aqueous solubility, and its
oral absorption is limited by its dissolution rate. The solubility and dissolution of gefitinib can …

Gefitinib is anticancer drug which is sparingly soluble in water. This limits its dissolution and
bioavailability. Binary inclusion complex of gefitinib with Epi-β-CD was prepared by freeze …

Cancer is the leading cause of mortality worldwide. In patients with metastatic non-small cell
lung cancer, epidermal growth factor receptor (EGFR) is often overexpressed. Gefitinib …

Background and Objective: Cyclodextrins have been of great interest as excellent
candidates for fabricating versatile nano-drug delivery systems due to their commercial …

Nitro-2H-chromene derivatives exhibit promising anticancer activities, but their clinical
translation is hindered by poor aqueous solubility. Herein, we report a cyclodextrin …

A series of molecular dynamics simulations were performed on 5-fluorouracil (5-Fu),
Alendronate (Ald), and Temozolomide (TMZ) anticancer drugs in the presence and absence …

Erlotinib (ERL) is a drug used in epidermoid carcinoma treatment. One of the ERL
drawbacks is low water solubility, which limits its use in the development of safer and …

Objectives Introduction of multiple molecules in a single inclusion complex, albeit cheaper,
lacks conclusive attempts in earlier drug delivery reports. This manuscript emphasizes …

Many chemotherapeutic drugs are therapeutically non-selective and do not distinguish
between healthy cells and tumour cells which can result in severe side effects and toxicity …